Elevance Health
783 hedge funds and large institutions have $33.7B invested in Elevance Health in 2016 Q4 according to their latest regulatory filings, with 113 funds opening new positions, 242 increasing their positions, 320 reducing their positions, and 52 closing their positions.
117% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 52
35% more funds holding in top 10
Funds holding in top 10: 20 → 27 (+7)
16% more capital invested
Capital invested by funds: $29.2B → $33.7B (+$4.56B)
7% more funds holding
Funds holding: 734 → 783 (+49)
0.24% less ownership
Funds ownership: 89.37% → 89.13% (-0.24%)
24% less repeat investments, than reductions
Existing positions increased: 242 | Existing positions reduced: 320
29% less call options, than puts
Call options by funds: $163M | Put options by funds: $228M
Top Buyers
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$188M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$147M |
| 3 |
O
OrbiMed
New York
|
+$137M |
| 4 |
TP
Third Point
New York
|
+$134M |
| 5 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
+$133M |
Top Sellers
ELV Hedge Fund Activity: Q4 2016 in Review
783 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q4 2016, worth a combined $33.7B — up 16% from $29.2B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new ELV positions and 52 closed out — a net gain of 61 holders — while 242 added to existing stakes and 320 trimmed.
The largest buyer was Boston Partners, adding an estimated $188M. The largest seller was JP Morgan Chase, cutting an estimated $161M.
- 783 institutional investors held Elevance Health (ELV) as of Q4 2016, up from 734 in Q3 2016.
- Funds reported $33.7B of Elevance Health stock for Q4 2016, up 16% quarter-over-quarter.
- 113 funds opened new Elevance Health positions in Q4 2016 and 52 closed out, a net change of +61 holders.
- The largest Elevance Health buyer in Q4 2016 was Boston Partners, an estimated $188M added.
- The largest Elevance Health seller in Q4 2016 was JP Morgan Chase, an estimated $161M sold.
Based on aggregated 13F filings for Q4 2016.